Loading company…
Cambridge, Massachusetts biotech developing epigenomic regulator therapies that control gene expression for rare and common diseases.
Founded in 2017 by Noubar Afeyan and David Berry and based in Massachusetts, Omega Therapeutics, Inc. is a development-stage genomic medicine company building engineered Epigenomic Regulators for rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. Mahesh Karande is President and CEO. As of 2021 the company had eight programs in preclinical development, after funding rounds in July 2020 and March 2021 and a confidential public filing in May 2021. It plans to advance OTX-2002 for hepatocellular carcinoma and to list on Nasdaq as OMGA.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in